Expert insights. Personalized for you.
Antibody Related Topics 
Bio Pharma Dive
JUNE 16, 2021
The biotech said it will seek an expanded FDA clearance after results from the RECOVERY trial showed its antibody can lower mortality among certain hospitalized COVID-19 patients
Bio Pharma Dive
NOVEMBER 5, 2020
Fast antibody testing, however, is spotty The drug, now being considered for emergency clearance by the FDA, seems to work best in patients whose immune systems haven't responded to infection.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
SEPTEMBER 17, 2021
The expanded authorization comes amid surging demand for antibody treatments, particularly in states with lower rates of coronavirus vaccination
Bio Pharma Dive
JULY 27, 2022
The companies pitch their collaboration as a way to give young drugmakers backed by Versant a head start. “Our business is advanced by great ideas coming into the funnel,” said AbCellera’s CEO
Bio Pharma Dive
NOVEMBER 9, 2020
The Food and Drug Administration cleared the company's synthetic antibody treatment, but short supplies and logistical challenges could limit its initial impact
Scienmag
MARCH 21, 2022
An international research team discovered the first human antibody to effectively neutralize two types of hantaviruses in animal models, according to a study published online Mar. Biology antibody developing hantavirus promise shows treatment
Bio Pharma Dive
FEBRUARY 10, 2021
In a late-stage study of people recently diagnosed with COVID-19, the dual-antibody drug sharply reduced the risk of hospitalizations and death
Scienmag
APRIL 25, 2022
GALVESTON, Texas – Researchers at the University of Texas Medical Branch recently confirmed the presence of neutralizing antibodies to SARS–COV-2 in a common subcutaneous antibody therapy (Hizentra) used to treat immunocompromised or immunodeficient patients, citing its protective benefits to the immunocompromised patient community. Latest News Antibodies antibody antiSARSCoV2 common shows study therapy UTMB
Scienmag
JUNE 15, 2022
Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM).
Scienmag
MAY 4, 2022
LA JOLLA, CA—Getting sick with a common cold doesn’t make you immune to COVID-19, but a COVID-19 infection might, at least temporarily, boost the number of antibodies you have against common cold-causing coronaviruses and the SARS-CoV-1 and MERS-CoV viruses, all of which are closely related.
Scienmag
JANUARY 21, 2022
A recent study looked at the strength, durability and breadth of neutralizing antibody responses generated by breakthrough infections in individuals vaccinated against SARS-CoV2. Medicine & Health antibody breakthrough COVID19 infections responses spur strong
Bio Pharma Dive
JUNE 18, 2021
drugmaker is the latest to invest large sums of money in antibody-drug conjugates, following recent deals by Gilead, Merck and AstraZeneca The U.S.
Scienmag
JULY 8, 2022
Researchers at the University of Southampton have gained unprecedented new insight into the key properties of an antibody needed to fight off cancer. The findings have enabled the Southampton team to design antibodies to […].
|
Bio Pharma Dive
OCTOBER 14, 2020
Research for the drug, now cleared as Inmazeb, helped Regeneron jumpstart its fast development of an antibody therapy for COVID-19
NY Times
FEBRUARY 9, 2021
internal-essential Drugs (Pharmaceuticals) Antibodies Coronavirus (2019-nCoV Researchers hope Eli Lilly’s new combination therapy may be better able to fight virus variants than a similar treatment already in use.
Bio Pharma Dive
APRIL 19, 2021
Adagio Therapeutics, a well-financed spinout of antibody developer Adimab, could challenge Regeneron and Eli Lilly if its drug candidate proves protective in clinical tests
Scienmag
MAY 13, 2022
LA JOLLA, CA—Last year, scientists at Scripps Research and Toscana Life Sciences studied the blood of 14 COVID-19 survivors to find the most potent antibodies against the SARS-CoV-2 virus. Medicine & Health antibody COVID19 explain J08 potent research scientists Scripps
Bio Pharma Dive
FEBRUARY 11, 2022
Distribution of Lilly's earlier antibody treatments was halted as testing showed them ineffective against omicron. Bebtelovimab appears able to neutralize the variant, and was authorized by the FDA on Friday
Bio Pharma Dive
MARCH 25, 2021
Treatments from Lilly and Regeneron that combine two different antibodies should be used instead, according to health officials
Bio Pharma Dive
DECEMBER 8, 2021
Evusheld, a combination of two antibodies, is meant to be long-acting, proving protective against disease through six months in clinical testing
Bio Pharma Dive
JULY 28, 2021
The acquisition is the third Amgen has made since March and broadens its ability to develop bispecific antibodies, a drug class of intense interest to big biotech
Bio Pharma Dive
MAY 24, 2021
Pharma and biotech companies alike see potential in using bispecific antibodies for hard-to-treat cancers like leukemia, myeloma and solid tumors
Scienmag
JULY 1, 2022
Now, investigators from Japan have developed a new antibody-based method for the rapid and reliable detection of SARS-CoV-2 […]. Medicine & Health antibody blood coronavirus detection method require sample
Scienmag
JANUARY 24, 2022
Cancer antibody bone Engineered metastasis peptide targetsHOUSTON – (Jan. 24, 2022) – A moderate amount of a peptide-enhanced, biological cancer drug goes a long way in treating breast cancers that metastasize to the bone.
NY Times
FEBRUARY 11, 2022
The federal government has ordered 600,000 doses of the monoclonal antibody treatment, which is meant for high-risk Covid patients early in their illness. Eli Lilly and Company Antibodies Food and Drug Administration Coronavirus Omicron Variant Drugs (Pharmaceuticals) Coronavirus (2019-nCoV
NY Times
MARCH 6, 2022
Shortages AstraZeneca PLC Immune System Antibodies Coronavirus (2019-nCoV) Chronic Condition (Health) Drugs (Pharmaceuticals) Transplants United States Politics and Government
Bio Pharma Dive
MARCH 29, 2022
The French pharmaceutical giant has inked its third antibody-focused deal since December, this time betting on a Californian biotech trying to pioneer a new class of medicines
Bio Pharma Dive
DECEMBER 23, 2021
The decision follows worrisome results in lab studies that indicated omicron can evade both drugs and leaves the U.S. with fewer treatments to respond to the variant's spread
Bio Pharma Dive
NOVEMBER 5, 2020
Buying VelosBio is Merck's second investment in so-called antibody-drug conjugates since September, reflecting the drug class' fast turnaround
Scienmag
APRIL 13, 2022
Medicine & Health antibody COVID19 current mice nasal outperforms spray treatmentsA new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St.
Scienmag
MARCH 24, 2022
Mayo Clinic researchers have validated a new antibody test to diagnose multiple sclerosis (MS), a potentially disabling disease of the brain and spinal cord. An antibody typically consists of two immunoglobulin heavy chains and […]. Latest News antibody Clinic develop diagnose Mayo researchers testROCHESTER, Minn. Nearly 1 million people in the U.S. are affected by MS, according to the National Multiple Sclerosis Society.
Pharma Phorum
MAY 18, 2022
Brand new UK startup RQ Biotechnology has been thrust into the spotlight after signing a $157 million licensing deal with AstraZeneca for monoclonal antibodies intended to protect vulnerable and immunosuppressed people from COVID-19.
Scienmag
MARCH 23, 2022
Technology and Engineering Antibodies approach COVID19 madeinCanada trackingWith every quiet pass of the robotic arm in a research lab at the Lunenfeld-Tanenbaum Research Institute (LTRI) in downtown Toronto, more questions about COVID-19 are being answered.
Pharma Phorum
SEPTEMBER 16, 2022
Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of newborns and infants from respiratory syncytial virus (RSV) infections. The post CHMP says yes to Sanofi/AstraZeneca antibody for RSV prevention appeared first on.
Pharma Phorum
JULY 6, 2021
Nina Garrett, R&D director at Abingdon Health discusses the key role antibody testing is playing in the pandemic and how an integrated approach with vaccines could help normal life resume. This is where antibody tests come in. Neutralising Antibodies.
Bio Pharma Dive
JANUARY 12, 2021
Moderna and Gilead reported billions in sales for their coronavirus treatments, but Regeneron's antibody drug cocktail hasn't gained traction.
Scienmag
JUNE 10, 2022
Researchers have known for some time that maternal breast milk provides critical nutrients for newborns, and antibodies from mothers vaccinated against a specific disease-causing bacterium or virus can be transferred via breast milk to babies. Now a new preclinical study by Weill Cornell Medicine investigators shows that one specific set of antibodies that is induced […]. Latest News Antibodies Bacteria breast gut IgG immunity infants milk shape
Scienmag
APRIL 20, 2022
BOSTON – According to new research from Boston Medical Center, the antibody function known as antibody dependent cellular cytotoxicity (ADCC) and the ADCC sensitivity of HIV strains may influence the transmission of HIV from mother to child during breastfeeding. Latest News ADCC antibody breastfeeding cellular child cytotoxicity dependent function HIV mother prevent transmission
Bio Pharma Dive
AUGUST 19, 2020
Together, the companies expect to make three and a half times as many doses of Regeneron's antibody drug than the U.S. biotech could on its own
Scienmag
NOVEMBER 2, 2021
However, in a newly published study, researchers at the University of Maryland School of Medicine (UMSOM) have detected antibodies primarily made in response to infections in the mucous membranes — in such areas as […].
Bio Pharma Dive
DECEMBER 8, 2020
But a growing group of antibody drugs, several of which were showcased at ASH, aren't far behind Two cell therapies might soon be approved for the blood cancer.
Scienmag
MARCH 24, 2022
A new study shows how antibodies select the antigens that they bind to, as they navigate the surface of pathogens like coronaviruses. Medicine & Health Antibodies child model navigate pathogen play shows surfaces
Bio Pharma Dive
OCTOBER 8, 2020
The two antibody treatments are now being reviewed by the FDA, although limited supply could mean their impact won't be felt for months, even if they are cleared for use
261 
Let's personalize your content